A Republican-run Medicare agency is now facing bipartisan backlash for pushing a Biden-era price-control scheme further than lawmakers say is wise, threatening to choke off new cancer treatments before patients even see them.
Story Snapshot
- More than 50 lawmakers from both parties sent a letter urging the Centers for Medicare & Medicaid Services (CMS) not to finalize a new “fixed-dose combination” drug rule.
- The rule would force improved drug combinations into Medicare price negotiations almost as soon as they get Food and Drug Administration (FDA) approval.
- The policy stems from the Inflation Reduction Act, the Biden-era law that already set 2027 negotiated prices for 15 Medicare Part D drugs.
- Sen. Chuck Grassley and the drug industry’s top trade group say price controls are already causing companies to abandon research into cancer and blindness treatments.
Bipartisan Letter Targets Fixed-Dose Drug Rule
More than 50 members of Congress from both parties sent a letter to CMS warning against finalizing a proposed policy on fixed-dose combination drugs. These are treatments that combine two or more existing medicines into one improved product. Lawmakers, including Reps. John Joyce, Darin LaHood, and Jim Costa, said the rule would rush these new combinations into government price talks right after they earn Food and Drug Administration approval.
The lawmakers argue this timing problem is not a small technical detail. Drug companies typically need years after approval to earn back what they spent developing a new combination therapy. If Washington sets a fixed price almost immediately, firms lose the financial cushion they count on. The letter warned this would harm both patient access and the incentive to build better drugs in the first place.
Inflation Reduction Act’s Price Control Machine
The dispute traces back to the Inflation Reduction Act, signed under President Biden in 2022, which gave Medicare the power to negotiate prices on select high-cost drugs for the first time. CMS has already selected 15 Part D drugs for a second round of negotiated “maximum fair prices” set to take effect January 1, 2027. Those cuts are real and sizable, with Medicare projected to pay billions less for drugs like Ibrance and semaglutide-based treatments next year.
The savings sound good on paper, and Republicans have never argued seniors should pay more than necessary for medicine. But the law’s mechanics keep creating side effects nobody voted for. The fixed-dose combination proposal is the latest example: a Trump-appointed CMS is now stuck administering a Biden-era statute that critics say punishes innovation by design, not by accident.
Innovation Warnings Mount From Both Parties
Sen. Chuck Grassley, R-Iowa, has been sounding the alarm on this law for months. He wrote that the government’s drug price controls “are already killing innovation,” pointing to drug makers who have abandoned research into treatments for certain cancers and blindness. Grassley argued that market competition, not Washington price-setting, is what actually improves medication access and affordability for seniors.
The Pharmaceutical Research and Manufacturers of America, the industry’s largest trade group, backs up that concern with its own numbers. The group says the law’s price-setting policies are expected to hurt access to medicines under both Medicare Part B and Part D, while discouraging the kind of drug development that leads to breakthrough treatments. Oncology practices are already feeling squeezed, with one panel discussion warning that shrinking reimbursement can limit the care doctors are able to provide patients.
Seniors Caught Between Savings and Access
Seniors are stuck in the middle of this fight. They want lower drug costs now, and the 2027 price cuts CMS finalized will genuinely lower what Medicare pays for several widely used medicines. But the same law creating those savings is also the reason bipartisan lawmakers are now begging CMS to slow down on a new rule they fear will scare drug companies away from building better treatments in the future.
A bipartisan group of over 50 lawmakers is urging the Trump administration to reconsider a proposed Medicare policy linked to the Biden-era drug pricing law. They argue that the policy could hinder the development of improved cancer treatments by exposing newer drug versions to… pic.twitter.com/jH1ubwxd3g
— Spot on 101 (@Spoton101) September 29, 2026
Conservatives have long warned that government price-setting, even when it delivers short-term savings, tends to carry hidden long-term costs. This fight shows that warning playing out in real time, inside an agency now run by a Trump administration forced to clean up a law it never wrote. Whether CMS backs off the fixed-dose rule will show if it’s listening to the doctors, patients, and lawmakers raising the alarm.
Sources:
foxnews.com, cms.gov, brookings.edu, ajmc.com, thehill.com, onclive.com
